Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesChetan Bettegowda, Jon Weingart, Mark Sausen et al.|Science Translational Medicine|2014Cited by 5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Livio Trusolino et al.|The Lancet Oncology|2016Cited by 1k
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ.-Y. Douillard, R. Sidhu, Salvatore Siena et al.|Annals of Oncology|2014Cited by 603
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Susie Jun, Karim Fizazi et al.|European Journal of Cancer|2012Cited by 588
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537